Michela Tindera Author Rss https://faqinsurances.com/author/michela-tindera/ Michela Tindera Author Rss - Faqs of Insurances Wed, 10 Apr 2024 00:00:28 +0000 en-US hourly 1 https://faqinsurances.com https://faqinsurances.com/public/skin/logo.png Michela Tindera Author Rss https://faqinsurances.com/author/michela-tindera/ 144 144 <![CDATA[A weight loss titan fights to stay relevant in the age of GLP-1 drugs ]]> https://faqinsurances.com/2024/04/10/a-weight-loss-titan-fights-to-stay-relevant-in-the-age-of-glp-1-drugs/ Wed, 10 Apr 2024 00:00:28 +0000 https://faqinsurances.com/2024/04/10/a-weight-loss-titan-fights-to-stay-relevant-in-the-age-of-glp-1-drugs/

Your browser does not support playing this file but you can still download the MP3 file to play locally.

WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.

Clip from Lionsgate Television

- - - - - - - - - - - - - - - - - - - - - - - - - -

For further reading:

WeightWatchers faces an era when weight loss comes in a syringe

Behold the Ozempic effect on business

The race to develop the next generation of weight-loss drugs

- - - - - - - - - - - - - - - - - - - - - - - - - -

On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.

Read a transcript of this episode on FT.com

View our accessibility guide.

This story originally appeared on: Financial Times - Author:Michela Tindera

]]> <![CDATA[Best Of: Inside Johnson & Johnson’s bankruptcy two-step]]> https://faqinsurances.com/2023/05/31/best-of-inside-johnson-johnsons-bankruptcy-two-step/ Wed, 31 May 2023 00:00:00 +0000 https://faqinsurances.com/2023/05/31/best-of-inside-johnson-johnsons-bankruptcy-two-step/

Your browser does not support playing this file but you can still download the MP3 file to play locally.

This week, we’re revisiting an episode from last year. Johnson & Johnson, one of the world’s largest healthcare companies, is facing thousands of lawsuits from people alleging they got cancer from using one of their oldest products: talc-based baby powder. To manage the growing liability, J&J deployed a controversial bankruptcy manoeuvre known as the Texas two-step. The FT’s US pharmaceutical correspondent Jamie Smyth helps us explore whether J&J’s use of this manoeuvre is setting a precedent for corporations to evade accountability in America. Plus, stick around for an update on what’s happened to the Texas two-step since this episode first aired.

Clip from NBC

For further reading:

Johnson & Johnson’s ‘Texas-two-step’ sparks outcry over US bankruptcy regime

Talc ruling a blow to J&J and the ‘Texas two-step’ bankruptcy jig

Talcum powder cancer claims target J&J’s new consumer carve-out

On Twitter, follow Jamie Smyth (@JamieSmythF) and Michela Tindera (@mtindera07)

Read a transcript of this episode on FT.com


View our accessibility guide.

This story originally appeared on: Financial Times - Author:Michela Tindera

]]>